Alex Barnes Dirk Hofmann Lesley-Ann Hall Sonja Klebe Réme Mountifield
10.20524/aog.2021.0582
Ann Gastroenterol
2021;34(3):447-448.
ocrelizumab colitis esophagitis immunotherapy inflammatory bowel disease
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/33948072/
Case Reports
PMC8079880
33948072
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
2021